Disrupting life science: How VHH antibodies will shape future research (registration required)
For over 25 years, researchers have explored how nanobodies can be utilized in many life science fields. They have been found to be particularly powerful as imaging tools to visualize developing structures and pathologies with greater resolution. VHH antibodies have been used to characterize protein conformation and ligand and receptor relationships. Numerous pharmaceutical applications have been pursued, from diagnosis and therapy to follow-up. Potential treatment uses for nanobodies include solid tumor cancers, Alzheimer’s disease, and even COVID-19. In 2019, the U.S. Food and Drug Administration approved caplacizumab, the first nanobody for the prevention of thrombosis in patients with acute coronary syndrome.
In this webinar, our diverse panel of thought leaders will discuss the potential impact of VHH antibodies on life science research and touch on how these tools will transform technologies for imaging, diagnostics, and therapeutics.
This webinar will last for approximately 60 minutes.